Pharma steps back from Hodgkin lymphoma: now what?

Lynch RC; Gopal AK

doi:10.1182/bloodadvances.2025017650

← 뒤로

Pharma steps back from Hodgkin lymphoma: now what?

0/5 보강

Blood advances 📖 저널 OA 99.1% 2021~2026 2025 Vol.9(23) p. 6218-6219

Lynch RC, Gopal AK

📖 무료 전문 🟢 PMC 전문 PMC12745000

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

↓ .bib ↓ .ris

APA Lynch RC, Gopal AK (2025). Pharma steps back from Hodgkin lymphoma: now what?. Blood advances, 9(23), 6218-6219. https://doi.org/10.1182/bloodadvances.2025017650

MLA Lynch RC, et al.. "Pharma steps back from Hodgkin lymphoma: now what?." Blood advances, vol. 9, no. 23, 2025, pp. 6218-6219.

PMID 41364449 ↗

DOI 10.1182/bloodadvances.2025017650

같은 제1저자의 인용 많은 논문 (1)

Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma.
British journal of haematology 2025